APA (7th ed.) Citation

Ott, P. A., Piha-Paul, S. A., Munster, P., Pishvaian, M. J., van Brummelen, E. M. J., Cohen, R. B., . . . Bennouna, J. (2017). Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Annals of Oncology, 28(5), 1036. https://doi.org/10.1093/annonc/mdx029

Chicago Style (17th ed.) Citation

Ott, P. A., et al. "Safety and Antitumor Activity of the Anti-PD-1 Antibody Pembrolizumab in Patients with Recurrent Carcinoma of the Anal Canal." Annals of Oncology 28, no. 5 (2017): 1036. https://doi.org/10.1093/annonc/mdx029.

MLA (9th ed.) Citation

Ott, P. A., et al. "Safety and Antitumor Activity of the Anti-PD-1 Antibody Pembrolizumab in Patients with Recurrent Carcinoma of the Anal Canal." Annals of Oncology, vol. 28, no. 5, 2017, p. 1036, https://doi.org/10.1093/annonc/mdx029.